← Back to Search

Other

Randomized crossover assignment for Hypoxic Ventilatory Response

Phase 1 & 2
Waitlist Available
Led By Christopher Bell, PhD
Research Sponsored by Colorado State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up aes will be monitored at the time of visit and during the follow up period of 7 to 14 days.

Summary

In low oxygen environments, such as high-altitude, some adults may become ill and suffer from acute mountain sickness. Further, all adults will find that exercising becomes much more difficult when compared with exercise at lower altitudes (e.g. sea-level). The purpose of this investigation is to study the effects of a new medicine called Aes-103. A company called AesRx, LLC makes this medicine. The active ingredient in the medicine is 5-Hydroxymethyl-2-Furfural (5HMF), a naturally occurring substance that can be found in coffee, honey, dried fruits, fruit juices, malt, barley, Balsamic vinegar and caramel.The investigators believe that Aes-103 may help people adjust to high-altitude quickly and prevent them from becoming ill. The purpose of the study is to determine if Aes-103 will promote endurance performance in low oxygen environments in healthy adult humans. Aes-103 is currently being investigated by AesRx, LLC (Newton, MA) in collaboration with the National Heart, Lung and Blood Institute of the NIH (Bethesda, MD) as a potential anti-sickling agent in sickle cell disease. Sickle-cell disease is characterized by problems in blood that prevent blood cells from carrying oxygen. Aes-103 might be able to help blood cells carry more oxygen. It is for this reason that the investigators in this study believe Aes-103 might help people adjust to high-altitude quickly. There are no known special safety considerations with the active ingredient in Aes-103 (5-HMF). In recent, placebo controlled, clinical safety tests, Aes-103 was given in single doses of 300 mg, 1000 mg,2000 mg and 4000 mg to healthy normal volunteers. Additionally, the toxicological effects of Aes-103 have been studied when given acutely, sub-acutely, and chronically in rodents, and for up to 28 days in dogs. Based on these safety studies, single doses of Aes-103 are expected to have no significant negative/toxicological effect at the doses being evaluated in this study.

Eligible Conditions
  • Hypoxic Ventilatory Response
  • Hypoxia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~aes will be monitored at the time of visit and during the follow up period of 7 to 14 days.
This trial's timeline: 3 weeks for screening, Varies for treatment, and aes will be monitored at the time of visit and during the follow up period of 7 to 14 days. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Primary Objective Endurance Exercise Performance
Secondary study objectives
Secondary Objective Safety and Tolerability

Trial Design

1Treatment groups
Experimental Treatment
Group I: Randomized crossover assignmentExperimental Treatment2 Interventions
Participants will receive, in a random order, a placebo prior to exercise in normoxia, a placebo prior to exercise in hypoxia, 1000 mg of Aes-103 prior to exercise in hypoxia, and 3000 mg of Aes-103 prior to exercise in hypoxia. Each intervention is separated by a 7 day washout period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
Aes-103
2013
Completed Phase 2
~40

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Colorado State UniversityLead Sponsor
132 Previous Clinical Trials
38,415 Total Patients Enrolled
AesRx, LLCIndustry Sponsor
Christopher Bell, PhDPrincipal InvestigatorColorado State University
3 Previous Clinical Trials
118 Total Patients Enrolled
~1 spots leftby Dec 2025